Investor Contact

Media & Investor Relations:
Roderick de Greef 
Chief Financial Officer
(425) 402 - 1400
rdegreef@BioLifeSolutions.com

Investor Relations

LHA Investor Relations
www.lhai.com
2121 Avenue of the Stars
Suite 2970
Los Angeles, CA 90067
Phone: 310-691-7100
Jody Cain: jcain@lhai.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc. 
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.

Press Releases

Cryomedical Sciences, Inc Announces Restructuring; Strategic Refocus On Commercialization of Bio-Packaging Technology; Agreement to Sell Cryosurgery Assets to Endocare
Announces New CEO, Proposed Name Change and New Strategic Focus on Proprietary Cell and Tissue Preservation Products
PRNewswire-FirstCall
KENNESAW, Ga.

Cryomedical Sciences, Inc. (BULLETIN BOARD: CRYM) (CMS) announced that it has executed a definitive agreement to sell its cryosurgical product line and related intellectual property assets to Irvine, CA-based Endocare, Inc. . In the transaction, Endocare will assume ownership of all of the cryosurgical installed base, regulatory approvals and intellectual property in exchange for $2.2 million in cash and approximately 120,000 shares of Endocare Common Stock. The consummation of the transaction is expected to occur in late June, and is subject to various customary conditions to closing.

The restructuring allows the Company to shift its business to focus on the continued development and marketing of its proprietary bio-packaging technology, which includes products that facilitate the development of cell and gene therapy techniques through the preservation and transportation of tissue and cellular material.

The Company also announced that it has named John G. Baust, Ph.D. to the position of President and CEO, replacing Andrew Greuling, who is leaving the Company in connection with the transaction. Dr. Baust has been the President of BioLife Solutions, Inc., which was incorporated as a wholly owned subsidiary of CMS in 1998. Dr. Baust pioneered and spearheaded the development and commercialization of the HypoThermosol® product line at BioLife. To complete the restructuring, the Board of Directors will propose changing the name of the Company to BioLife Solutions, Inc.

Dr. Baust said that the sale of cryosurgical assets opens the door for a compelling market opportunity and that the future direction of the organization is positive for a number of reasons, including new funding, a promising product line that satisfies an immense and growing need in biotechnology and medicine, and a refocused strategy for success.

"This transaction will provide approximately 25 cents per outstanding CMS share in cash and marketable securities and provides the necessary capital to fully commercialize our proprietary bio-packaging technology, without further dilution to our current shareholders.

"In the coming weeks we will completely reposition the Company to address the emerging market for products that prolong cell life and sustain the integrity of tissue and cellular material. The emergence of adult stem cell and other forms of cell therapy, has created a need for effective means of transportation and storage of biological material, while keeping it viable for extended periods. We have produced a range of enabling products that meet these needs and are currently selling these products commercially. We have already signed agreements with several leading biotechnology companies to customize our products for their specific applications."

About BioLife Solutions, Inc.

The methods for preserving cells, tissue and organs have remained largely unchanged for 50 years. BioLife Solutions, Inc., a wholly owned subsidiary of Cryomedical Sciences, Inc., has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol® and CryoStor™ products that the Company is selling today are a significant step forward in meeting these needs.

For further information, please contact Investors: Jill Cieslak, jill@allencaron.com, or Media: Len Hall, len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, http://www.allencaron.com/, for Cryomedical Sciences, Inc.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X23253336

SOURCE: Cryomedical Sciences, Inc.

CONTACT: Investors: Jill Cieslak, jill@allencaron.com, or Media: Len
Hall, len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, for
Cryomedical Sciences, Inc.